Abstract
AimsAs part of the care of breast cancer patients considered for trastuzumab, the measurement of LV ejection fraction (EF) pre-treatment is required. Current protocols recommend that EF is then repeated...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
